| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 04/05/2001 | WO2001023550A2 Pca3 messenger rna species in benign and malignant prostate tissues |
| 04/05/2001 | WO2001023547A1 26 human secreted proteins |
| 04/05/2001 | WO2001023546A1 37 human secreted proteins |
| 04/05/2001 | WO2001023540A2 P-glycoproteins and uses thereof |
| 04/05/2001 | WO2001023427A1 Polypeptide derivatives of parathyroid hormone (pth) |
| 04/05/2001 | WO2001023408A1 5-hydroxysapogenin derivatives with anti-dementia activity |
| 04/05/2001 | WO2001023406A1 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia |
| 04/05/2001 | WO2001023402A1 43 human secreted proteins |
| 04/05/2001 | WO2001023398A1 Novel fucosylated oligosaccharides and process for their preparation |
| 04/05/2001 | WO2001023391A1 Triazolopurine derivatives, drug compositions containing the same and adenosine a3 receptor affinitive agents |
| 04/05/2001 | WO2001023389A2 Certain alkylene diamine-substituted heterocycles |
| 04/05/2001 | WO2001023388A2 AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES |
| 04/05/2001 | WO2001023387A2 CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES |
| 04/05/2001 | WO2001023386A2 Benzodiazepin derivatives, the production and use thereof |
| 04/05/2001 | WO2001023385A2 Novel tropane analogs |
| 04/05/2001 | WO2001023383A1 Quinuclidine compounds and drugs containing the same as the active ingredient |
| 04/05/2001 | WO2001023382A1 Pharmaceutically active sulfonyl hydrazide derivatives |
| 04/05/2001 | WO2001023381A1 Piperidine derivatives as reuptake inhibitors |
| 04/05/2001 | WO2001023380A1 Piperidine derivatives as serotonine reuptake inhibitors |
| 04/05/2001 | WO2001023379A1 Pharmaceutically active sulfonyl amino acid derivatives |
| 04/05/2001 | WO2001023378A1 Pharmaceutically active sulfonamide derivatives |
| 04/05/2001 | WO2001023377A2 Polymorphic salt |
| 04/05/2001 | WO2001023374A1 Piperazine derivatives as 5-ht1b antagonists |
| 04/05/2001 | WO2001023360A1 Aryl sulfonamide-substituted benzimidazol derivatives thereof as tryptase inhibitors |
| 04/05/2001 | WO2001023359A1 Aryl-sulfonamide substituted benzimidazol derivatives and use of said as tryptase inhibitors |
| 04/05/2001 | WO2001023357A2 Fused cycloheptane and fused azacycloheptane compounds and their use as integrin receptor antagonists |
| 04/05/2001 | WO2001023347A1 Novel aromatic compounds |
| 04/05/2001 | WO2001023006A1 Low dose ifn-gamma for treatment of disease |
| 04/05/2001 | WO2001022990A2 Methods related to immunostimulatory nucleic acid-induced interferon |
| 04/05/2001 | WO2001022987A1 Trail: an inhibitor of autoimmune inflammation and cell cycle progression |
| 04/05/2001 | WO2001022977A2 Echinacea supplement and method of manufacture |
| 04/05/2001 | WO2001022969A2 Vasopressin agonist formulation and process |
| 04/05/2001 | WO2001022967A1 Compositions having improved stability |
| 04/05/2001 | WO2001022966A1 Caspases and apoptosis |
| 04/05/2001 | WO2001022961A1 New use of modafinil and the d/l enantiomer |
| 04/05/2001 | WO2001022951A2 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis |
| 04/05/2001 | WO2001022945A1 Vasopressin antagonist formulation and process |
| 04/05/2001 | WO2001022944A1 Oral controlled release formulations |
| 04/05/2001 | WO2001022937A1 Compositions of tocol-soluble therapeutics |
| 04/05/2001 | WO2001022923A2 Scar treatment composition |
| 04/05/2001 | WO2001012602A8 Condensed indoline derivatives and their use as 5ht, in particular 5ht2c, receptor ligands |
| 04/05/2001 | WO2001006015A8 NOVEL GLYCOSYL SULFOTRANSFERASES GST-4α, GST-4β, AND GST-6 |
| 04/05/2001 | WO2001005397A8 Procyanidin oligomers inhibiting matrix metalloproteinases and medicine having effective composition of the same |
| 04/05/2001 | WO2001002422A9 PROCESS FOR OBTAINING 17β-(N-TERC-BUTYLCARBAMOYL)-3-ONE-4-AZA-STEROIDS |
| 04/05/2001 | WO2001002400A8 Fused imidazole compounds and remedies for diabetes mellitus |
| 04/05/2001 | WO2000073450A3 Cytoskeleton-associated proteins |
| 04/05/2001 | WO2000073334A3 Human sorting nexins |
| 04/05/2001 | WO2000072867A3 Substantially oil-free cyclosporin compositions |
| 04/05/2001 | WO2000068198A3 Heterosubstituted pyridine derivatives as pde 4 inhibitors |
| 04/05/2001 | WO2000066752A3 Gene construct for prodrug activation encoding a heterologous, glycosylphophati dylinositol-modified carboypeptidase g2 and a cell surface targettng signal peptide |
| 04/05/2001 | WO2000057877A8 Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof |
| 04/05/2001 | WO2000057863A3 Use of pyridoxine compounds for treatment of cardiovascular and related pathologies |
| 04/05/2001 | WO2000056891A3 Human transmembrane proteins |
| 04/05/2001 | WO2000051547A3 Inhibitors of prenyl-protein transferase |
| 04/05/2001 | WO2000047197A3 Alkylating agents for treatment of cellular proliferation |
| 04/05/2001 | WO2000044362A3 The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation |
| 04/05/2001 | WO2000030668A9 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration |
| 04/05/2001 | WO1996018391B1 Use of mono and bicarboxylic acid amides for the manufacture of a medicament active at the peripheral cannabinoid receptor |
| 04/05/2001 | US20010000179 Inhibitors of typsin-like serine protease; anticoagulants |
| 04/05/2001 | DE19948679A1 Nucleic acid sequences from human endothelial cells, useful for gene therapy of angiogenesis and for identifying antiangiogenic agents |
| 04/05/2001 | DE19947457A1 New 2'-aminomethyl-biphenyl-2-carboxamide derivatives, are potassium channel blockers especially useful for treating re-entry or supraventricular arrhythmia or atrial fibrillation or flutter |
| 04/05/2001 | DE19947010A1 Das Gen PRV-1 und dessen Verwendung The PRV-1 gene and its use |
| 04/05/2001 | CA2640998A1 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia |
| 04/05/2001 | CA2388474A1 Vasopressin antagonist formulation and process |
| 04/05/2001 | CA2388005A1 Low dose ifn-gamma for treatment of disease |
| 04/05/2001 | CA2387702A1 The prv-1 gene and use thereof |
| 04/05/2001 | CA2386092A1 Piperidine derivatives |
| 04/05/2001 | CA2386085A1 Piperidine derivatives |
| 04/05/2001 | CA2386029A1 P-glycoproteins from macaca fascicularis and uses thereof |
| 04/05/2001 | CA2386002A1 Trail: an inhibitor of autoimmune inflammation and cell cycle progression |
| 04/05/2001 | CA2385990A1 Compositions having improved stability |
| 04/05/2001 | CA2385989A1 Compositions of tocol-soluble therapeutics |
| 04/05/2001 | CA2385971A1 Vasopressin agonist formulation and process |
| 04/05/2001 | CA2385887A1 Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors |
| 04/05/2001 | CA2385884A1 26 human secreted proteins |
| 04/05/2001 | CA2385865A1 Triazolopurine derivatives, pharmaceutical compositions containing the derivatives, and adenosine a3 receptor affinitive agents |
| 04/05/2001 | CA2385737A1 Piperazine derivatives as 5-ht1b antagonists |
| 04/05/2001 | CA2385490A1 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis |
| 04/05/2001 | CA2385295A1 Novel fucosylated oligosaccharides and process for their preparation |
| 04/05/2001 | CA2385169A1 43 human secreted proteins |
| 04/05/2001 | CA2385001A1 Pharmaceutically active sulfonyl hydrazide derivatives |
| 04/05/2001 | CA2384997A1 Pharmaceutically active sulfonyl amino acid derivatives |
| 04/05/2001 | CA2384981A1 P-glycoproteins and uses thereof |
| 04/05/2001 | CA2384692A1 Novel tropane analogs |
| 04/05/2001 | CA2384659A1 37 human secreted proteins |
| 04/05/2001 | CA2384509A1 Scar treatment composition |
| 04/05/2001 | CA2384265A1 Benzodiazepin derivatives, the production and use thereof |
| 04/05/2001 | CA2382892A1 Substituted benzimidazol derivatives, processes for preparing them and their use as pharmaceutical compositions |
| 04/05/2001 | CA2381771A1 Methods and compositions relating to sodium channel beta1a subunits |
| 04/05/2001 | CA2379595A1 Oral controlled release formulations |
| 04/04/2001 | EP1088900A1 Polymorphisms in the human CYP3A4, CYP3A7 and hPXR genes and their use in diagnostic and therapeutic applications |
| 04/04/2001 | EP1088824A2 Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors |
| 04/04/2001 | EP1088823A1 Fused pyrrolocarbazoles |
| 04/04/2001 | EP1088822A1 Pharmaceutically active sulfonyl hydrazide derivatives |
| 04/04/2001 | EP1088821A1 Pharmaceutically active sulfonamide derivatives |
| 04/04/2001 | EP1088815A1 Pharmaceutically active sulfonyl amino acid derivatives |
| 04/04/2001 | EP1088550A1 alpha-sulfonylamino hydroxamic acid inhibitors of matrix metallo-proteinases for the treatment of peripheral or central nervous system disorders |
| 04/04/2001 | EP1088333A1 Compositions and methods for inhibiting bone resorption |
| 04/04/2001 | EP1088100A2 Proteasomal activity |
| 04/04/2001 | EP1088098A2 Fitness assay and associated methods |